These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30927174)

  • 21. Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy.
    Takamatsu K; Mizuno R; Omura M; Morita S; Matsumoto K; Shinoda K; Kosaka T; Takeda T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
    Clin Genitourin Cancer; 2018 Aug; 16(4):e927-e933. PubMed ID: 29678472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
    Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
    Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 24. Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma.
    Takahara K; Ando R; Kanao K; Ito T; Miyake H; Sumitomo M; Yasui T; Shiroki R
    Anticancer Res; 2020 Aug; 40(8):4395-4400. PubMed ID: 32727768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma.
    Nader Marta G; Isaacsson Velho P; Bonadio RRC; Nardo M; Faraj SF; de Azevedo Souza MCL; Muniz DQB; Bastos DA; Dzik C
    Pathol Oncol Res; 2020 Oct; 26(4):2489-2497. PubMed ID: 32583330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
    Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
    Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
    Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
    Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
    Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
    Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma.
    Wang B; Gu W; Wan F; Shi G; Ye D
    Int Braz J Urol; 2019; 45(1):89-99. PubMed ID: 29570259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab.
    Nakayama T; Takeshita H; Kagawa M; Washino S; Shirotake S; Miura Y; Hyodo Y; Izumi K; Inoue M; Matsuoka Y; Miyagawa T; Oyama M; Saito K; Kawakami S
    Int J Clin Oncol; 2024 Oct; 29(10):1528-1537. PubMed ID: 39046676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Wells JC; Stukalin I; Norton C; Srinivas S; Lee JL; Donskov F; Bjarnason GA; Yamamoto H; Beuselinck B; Rini BI; Knox JJ; Agarwal N; Ernst DS; Pal SK; Wood LA; Bamias A; Alva AS; Kanesvaran R; Choueiri TK; Heng DY
    Eur Urol; 2017 Feb; 71(2):204-209. PubMed ID: 27318422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.
    Takamatsu K; Mizuno R; Tanaka N; Takeda T; Morita S; Matsumoto K; Kosaka T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
    Int J Clin Oncol; 2019 Sep; 24(9):1069-1074. PubMed ID: 31065836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
    Demircan NC; Alan Ö; Başoğlu Tüylü T; Akın Telli T; Arıkan R; Çiçek FC; Ercelep Ö; Öztürk MA; Alsan Çetin İ; Ergelen R; Tinay İ; Akgül Babacan N; Kaya S; Dane F; Yumuk PF
    J Oncol Pharm Pract; 2020 Jul; 26(5):1147-1155. PubMed ID: 31793376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
    Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
    Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
    Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
    Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
    Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Young M; Tapia JC; Szabados B; Jovaisaite A; Jackson-Spence F; Nally E; Powles T
    Clin Genitourin Cancer; 2024 Jun; 22(3):102072. PubMed ID: 38615487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.